Project Grant R00HL172253
Award Date
5/1/25
Completion Date
4/30/28
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
The $814,209 federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop a novel nanoparticle-based gene therapy approach for in vivo hematopoietic stem cell (HSC) modification. The project aims to optimize nanoparticle formulations that can deliver next-generation gene-editing agents and target the HSC-enriched cell population identified in the researchers' prior...
This federal Project Grant award, valued at $1,030,417.00 and issued by the National Heart, Lung, and Blood Institute (NHLBI), supports comprehensive research to understand the role of extracellular vesicles (EVs) in the increased risk of cardiovascular disease (CVD) among people living with HIV (PLWH). The research aims to characterize the molecular mechanisms by which EVs may contribute to inflammation and atherosclerosis progression in this population. The grant funds a multi-faceted research...
This $2,178,522 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is supporting research to develop enhanced chimeric antigen receptor (CAR) T-cell therapies targeting HIV. The overarching goal is to generate a more potent HIV-specific CAR T-cell product capable of effectively killing HIV-infected cells expressing low levels of the viral antigen. To achieve this, the research team is...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to understand and treat HIV-associated chronic obstructive pulmonary disease (COPD) through a CRISPR-based approach. The $472,980 award to Florida International University aims to identify the mechanisms by which HIV and cigarette smoke dysregulate microRNA expression, leading to mitochondrial dysfunction, cellular...
The federal Project Grant award R01HL174066 was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $771,902 award will fund research to examine the effects of extracellular vesicles containing the HIV-associated protein Nef (Nef EVs) on macrophage heterogeneity and atherosclerosis formation in people living with HIV on antiretroviral therapy. The research aims to identify novel mechanisms and therapeutic...
This $760,760 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate novel mechanisms underlying HIV-associated pulmonary vascular disease (PVD). The key research objectives are to determine whether HIV-derived proteins, particularly HIV-Tat, contribute to the development of PVD through CD4+ T cell-mediated, IL-1α-induced, and podocan-like protein 1 (PODNL1)-dependent...
This federal Project Grant award provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program, totaling $205,153, will fund research to investigate the potential role of pulmonary arterial smooth muscle cells (PVSMC) as reservoirs for HIV. The research aims to determine PVSMC's ability to sustain chronic HIV infection and spread the virus to other immune cells during antiretroviral therapy (ART)....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), will provide $641,960 to Augusta University Research Institute, Inc. to investigate the mechanisms of HIV-associated hypertension. The research, funded under the NIH's Cardiovascular Diseases Research program (CFDA 93.837), will test the hypothesis that HIV-derived proteins, specifically the Tat protein, contribute to the development of...
This Project Grant award, totaling $624,902, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The funding will support research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and HIV persistence in myeloid cells. The goals are to characterize how Vpr remodels the nuclear...
This federal Project Grant award, valued at $210,600.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Georgetown University focused on understanding the role of granzymes, a type of immune cell protein, in promoting vascular inflammation and injury in people living with HIV. The key objectives of this 2-year research project are to: 1) characterize how memory CD8 T...